TG Therapeutics, Inc. (TGTX)
64.48
-0.08
(-0.12%)
USD |
NASDAQ |
Nov 13, 16:00
64.48
0.00 (0.00%)
After-Hours: 19:59
TG Therapeutics EPS Diluted (Quarterly) : 0.3557 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.3557 |
| June 30, 2026 | 0.0495 |
| March 31, 2026 | 0.1236 |
| December 31, 2025 | 0.1446 |
| September 30, 2025 | 2.428 |
| June 30, 2025 | 0.1734 |
| March 31, 2025 | 0.0311 |
| December 31, 2024 | 0.1456 |
| September 30, 2024 | 0.0241 |
| June 30, 2024 | 0.0432 |
| March 31, 2024 | -0.0732 |
| December 31, 2023 | -0.1008 |
| September 30, 2023 | 0.7309 |
| June 30, 2023 | -0.3365 |
| March 31, 2023 | -0.2796 |
| December 31, 2022 | -0.3865 |
| September 30, 2022 | -0.2647 |
| June 30, 2022 | -0.3006 |
| March 31, 2022 | -0.5135 |
| December 31, 2021 | -0.7041 |
| September 30, 2021 | -0.647 |
| June 30, 2021 | -0.5944 |
| March 31, 2021 | -0.6871 |
| December 31, 2020 | -0.7109 |
| September 30, 2020 | -0.7314 |
| Date | Value |
|---|---|
| June 30, 2020 | -0.4707 |
| March 31, 2020 | -0.4847 |
| December 31, 2019 | -0.4137 |
| September 30, 2019 | -0.6907 |
| June 30, 2019 | -0.4172 |
| March 31, 2019 | -0.4331 |
| December 31, 2018 | -0.6422 |
| September 30, 2018 | -0.434 |
| June 30, 2018 | -0.5944 |
| March 31, 2018 | -0.5879 |
| December 31, 2017 | -0.46 |
| September 30, 2017 | -0.48 |
| June 30, 2017 | -0.448 |
| March 31, 2017 | -0.5216 |
| December 31, 2016 | -0.48 |
| September 30, 2016 | -0.50 |
| June 30, 2016 | -0.33 |
| March 31, 2016 | -0.28 |
| December 31, 2015 | -0.37 |
| September 30, 2015 | -0.28 |
| June 30, 2015 | -0.38 |
| March 31, 2015 | -0.35 |
| December 31, 2014 | -0.48 |
| September 30, 2014 | -0.51 |
| June 30, 2014 | -0.36 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Amneal Pharmaceuticals, Inc. | -0.0646 |
| Vertex Pharmaceuticals, Inc. | 2.561 |
| Regeneron Pharmaceuticals, Inc. | 18.45 |
| SELLAS Life Sciences Group, Inc. | -0.0508 |
| Travere Therapeutics, Inc. | -0.645 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 55.46M |
| Revenue (Quarterly) | 259.94M |
| Total Expenses (Quarterly) | 204.47M |
| Enterprise Value | 10.01B |
| Gross Profit Margin (Quarterly) | 83.81% |
| Profit Margin (Quarterly) | 21.34% |
| Earnings Yield | 1.04% |
| Operating Earnings Yield | 1.89% |
| Normalized Earnings Yield | 1.118 |